- Home
- GEN vs BIIB Comparison
GEN vs BIIB Comparison
Compare GEN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- BIIB
- Stock Information
- Founded
- GEN 1982
- BIIB 1978
- Country
- GEN United States
- BIIB United States
- Employees
- GEN N/A
- BIIB 7605
- Industry
- GEN Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GEN Technology
- BIIB Health Care
- Exchange
- GEN Nasdaq
- BIIB Nasdaq
- Market Cap
- GEN 16.9B
- BIIB 24.2B
- IPO Year
- GEN N/A
- BIIB 1991
- Fundamental
- Price
- GEN $26.81
- BIIB $168.52
- Analyst Decision
- GEN Buy
- BIIB Buy
- Analyst Count
- GEN 7
- BIIB 24
- Target Price
- GEN $35.43
- BIIB $174.62
- AVG Volume (30 Days)
- GEN 4.8M
- BIIB 1.7M
- Earning Date
- GEN 11-06-2025
- BIIB 10-30-2025
- Dividend Yield
- GEN 1.87%
- BIIB N/A
- EPS Growth
- GEN N/A
- BIIB N/A
- EPS
- GEN 0.91
- BIIB 10.97
- Revenue
- GEN $4,473,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- GEN $24.70
- BIIB $2.97
- Revenue Next Year
- GEN $4.97
- BIIB N/A
- P/E Ratio
- GEN $29.34
- BIIB $15.27
- Revenue Growth
- GEN 16.15
- BIIB 4.77
- 52 Week Low
- GEN $22.74
- BIIB $110.04
- 52 Week High
- GEN $32.22
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- GEN 48.77
- BIIB 74.64
- Support Level
- GEN $24.35
- BIIB $151.83
- Resistance Level
- GEN $27.29
- BIIB $157.79
- Average True Range (ATR)
- GEN 0.64
- BIIB 5.59
- MACD
- GEN 0.16
- BIIB 1.37
- Stochastic Oscillator
- GEN 80.75
- BIIB 95.37
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).